Clinical Trial Search

Primary: Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24 — 0; 0; 0; 10.0 percentage of…

Primary: Change in Lipidomic Profiles

Primary: Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period — 1.2; 3.0 Percentage of participants — p=0.1509

Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) — 6; 5; 5; 10 Participants

Primary: Change on Visual Acuity (VA) of the Treated Eyes From Baseline to the End of the Study — 36; 16; 4 Eyes

Primary: Time-to-QOL Improvement Defined as Any Increase in the QOL Score Measured Using the Total Score of the 14-item Postoperative Quality of Life (PQL) Tool — 4.86; 3.29 Months

Primary: Therapeutic Success — 756 Participants

Primary: Change in Clinician Administered PTSD Scale (CAPS) — -20.67 units on a scale

Primary: Overall Response Rate (ORR) — 70.4 percentage of participants

Primary: Salivary Cortisol Level

Primary: Difference Between Systolic Manual Sphygmomanometer and Finger Pulse Oximeter Readings — 3; 3; 11 mmHg

Primary: Dose Escalation Phase: Maximum Tolerated Dose (MTD) — 6; 40; 9; 7 milligrams (mg)

Primary: Participant Ratings (0-6) for Satisfaction, Usefulness of the Information Presented, Relevance, Ease of Understanding, and Likelihood to Use Skills Learning — 5.9; 5.9…

Primary: Percentage of Patients Alive and Progression Free Survival at 12 Weeks — 47 percentage of patients

Primary: Maximum Severity of Reactogenicity by Vaccination — 1; 0; 0; 0 Participants